Kyverna Therapeutics, Inc. KYTX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s total liabilities & equity?
- Kyverna Therapeutics, Inc. (KYTX) reported total liabilities & equity of $257.02M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s total liabilities & equity changed year-over-year?
- Kyverna Therapeutics, Inc.'s total liabilities & equity decreased by 1.4% year-over-year, from $260.66M to $257.02M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s total liabilities & equity?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s total liabilities & equity has grown at a 97.7% compound annual growth rate (CAGR), from $75.2M to $293.83M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.